3 key takeaways from ASCO 2025: Staying nimble in a changing environment
3 key takeaways from ASCO 2025: Staying nimble in a changing environment The annual meeting of the American Society of Clinical Oncology (ASCO) is a chance for oncology professionals, patient advocates, data experts, and industry representatives to come together and share the latest research in cancer care. This year, thousands of attendees descended on Chicago […]
Reflections on ISPOR: Shifting data dynamics open new opportunities for RWD and RWE
Each year, ISPOR brings together members of the health economics and outcomes research (HEOR) community for a celebration of the latest research and innovative methodology to push forward data-driven, patient-centered decision-making across the life sciences. It’s an event that never disappoints. Between the presentations of innovative research projects, experts sharing their knowledge in information sessions, […]
How real-world ovarian cancer data will improve outcomes for women
As we recognize Women’s Health Month and approach Mother’s Day, this is a chance to lead differently. We can ask better questions. We can design smarter trials. We can act on data that reflects real life, not just ideal scenarios. One in eight women will develop breast cancer during their lifetime. This year alone in […]
Minimizing “missingness” in cancer mortality statistics with real-world data
How real-world data can tell the story of breast, ovarian and uterine cancers at a pivotal moment in women’s health Nearly 4 million women worldwide are diagnosed with breast or gynecological cancers each year. Yet too many factors around these diseases are still poorly understood, including why there are so many disparities and variances in […]
How real-world data can tell the story of breast, ovarian and uterine cancers at a pivotal moment in women’s health
Nearly 4 million women worldwide are diagnosed with breast or gynecological cancers each year. Yet too many factors around these diseases are still poorly understood, including why there are so many disparities and variances in treatment and outcomes. Clinical trials have been helpful in illuminating some of these issues. And early approaches to leveraging real-world […]
Expanding insights into cancer with real-world data on solid tumors
Cancer comes in many forms, including hematologic malignancies that originate in blood-forming tissues or in the cells of the immune system, and solid tumors that form as abnormal masses of tissue and are named for the type of cells and classified by the organ or biologic structure from which they originate. Hematologic cancers, such as […]
Sustainability spotlight: How COTA is approaching corporate ecological responsibility
Since the turn of the century, there’s been a growing recognition that the health of our friends, families, & communities is intimately tied to the health of our physical environment. Safe water, clean air, & a diverse, balanced ecosystem are essential conditions for life to thrive & innovation to flourish.As a company focused on healthcare […]
Using AI to transform life sciences data analysis
Using AI to transform life sciences data analysis: An early look at CAILIN’s performance COTA has launched the COTA AI Language Insights Network (CAILIN) to expedite data analytics. CAILIN is an oncology trained, on-demand insight generator designed to answer a variety of fundamental questions pertaining to data analytics, including specific cohort size, subgroup breakdowns, […]
COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics
NEW YORK–(BUSINESS WIRE)–COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of COTA’s research-grade electronic health record (EHR) data from academic and community care centers and Guardant’s clinicogenomic […]
Study Results from COTA, PreciseDx, and Baptist Health South Florida Confirm Novel AI Test, PreciseBreast is Equivalent to Oncotype DX at Predicting Breast Cancer Recurrence
Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ — COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida today announced new study results validating the artificial intelligence […]
